Onkologie. 2024:18(4):266-270 | DOI: 10.36290/xon.2024.055

Efficacy of trifluridine/tipiracil plus bevacizumab in clinical practice

Stanislav Batko1, Jiří Pudil2
1 Onkologická klinika, FN Motol a 2. LF UK, Praha
2 Chirurgická klinika, 2. LF UK a ÚVN, Praha

The treatment of metastatic colorectal cancer involves a multimodal approach inclu­ding systemic treatment with chemotherapy, targeted therapy or immunotherapy, and where possible surgical intervention or other local methods as well. In the third line and beyond, clinicians' expectations have tended to be modest, however advances in new treatment combinations have expanded our options and shown the possibility of persistent treatment responses. This case report demonstrates the case of a patient with a pre-treated disease where trifluridine/tipiracil with bevacizumab led to a durable response. Trifludine/tipiracil in third-line therapy represents an effective and well-tolerated option suitable for the vast majority of patients.

Keywords: metastatic colorectal cancer, liver resection, trifluridin/tipiracil, bevacizumab, third line.

Accepted: October 1, 2024; Published: October 7, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Batko S, Pudil J. Efficacy of trifluridine/tipiracil plus bevacizumab in clinical practice. Onkologie. 2024;18(4):266-270. doi: 10.36290/xon.2024.055.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF

    References

    1. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [online]. Brno: Masarykova univerzita; 2005. [cit. 2024-6-12]. Available from: http://www.svod.cz. Verze 7.0 [2007].
    2. Prager GW, Taieb J, Fakih M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. The New England Journal of Medicine. 2023;388(18):1657-1667. Go to original source... Go to PubMed...
    3. Yoshino T, Cervantes A, Bando H, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treat­ment and follow-up of patients with metastatic colorectal cancer. ESMO Open. 2023;8(3):101558. doi: 10.1016/j.esmoop.2023.101558. Epub 2023 May 24. PMID: 37236086; PMCID: PMC10220270 Go to original source... Go to PubMed...
    4. Siravegna G, Bardelli A. Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer. Annals of Oncology. 2019;30(2):157-159. Go to original source... Go to PubMed...
    5. Cremolini C, Rossini D,Dell'Aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5:343-350. Go to original source... Go to PubMed...
    6. Martinelli E, Martini G,Famiglietti V, et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 2021;7:1529-1535. Go to original source... Go to PubMed...
    7. Ciardiello D, Martinelli E, Troiani T, et al. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial. JAMA Netw Open. 2024;7(4):e245635. doi:10.1001/jamanetworkopen.2024.5635. Go to original source... Go to PubMed...
    8. Napolitano S, Martini G, Ciardiello D, et al. CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients. Front Oncol. 2022;12:940523. doi: 10.3389/fonc.2022.940523. Go to original source... Go to PubMed...
    9. Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicen­tre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738-746. Go to original source... Go to PubMed...
    10. Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: an updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study. Lancet Oncol. 2019;20:518-530. Go to original source... Go to PubMed...
    11. Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24(5):496-508. doi: 10.1016/S1470-2045(23)00150-X. PMID: 37142372. Go to original source... Go to PubMed...
    12. Yoshino T, Di Bartolomeo M, Raghav K, et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal can­cer. Nat Commun. 2023;14:3332. https://doi.org/10.1038/s41467-023-38032-4. Go to original source... Go to PubMed...
    13. Raghav KPS, Siena S, Kato T, et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. JCO. 2023;41:3501-350. doi: 10.1200/JCO.2023.41.16_suppl.3501. Go to original source...
    14. Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRAS (G12C) somatic mutations across race, sex, and cancer type. N Engl J Med. 2021;384:185-187. Go to original source... Go to PubMed...
    15. Salem M, El-Refai S, Sha W, et al. Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies. Presented at the ESMO Congress 2021, virtual meeting. 2021; September 16-21. Go to original source...
    16. Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. The New England Journal of Medicine. 2023;388(1):44-54. Go to original source... Go to PubMed...
    17. Garmezy B, Gheeya J, Lin HY, et al. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precis Oncol. 2022;6:e2100267. doi: 10.1200/PO.21.00267. PMID: 35108036; PMCID: PMC8820927. Go to original source... Go to PubMed...
    18. Pietrantonio F, Di Nicolantonio F, Schrock AB, et al. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Can­cer. J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx089. PMID: 29370427. Go to original source... Go to PubMed...
    19. Garralda E, Hong D, Xu R, et al. SO-31 Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An expanded dataset. Annals of Oncology. June 2022;33:S370. Go to original source...
    20. Mayer RJ, Ohtsu A, Yoshino T, et al. TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial. JCO. 2016;34:634-634. doi: 10.1200/jco.2016.34.4_suppl.634. Go to original source...
    21. Tabernero J, Argiles G, Sobrero AF, et al. Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis. ESMO Open. 2020;5(4):e000752. Go to original source... Go to PubMed...
    22. Tabernero J, Prager GW, Taieb J. Impact of colorectal liver metastasis (CRLM) in patients with mCRC recieveing FTD/TPI with or without bevacizumab in the phase 3 SUNLIGHT Trial. ASCO 2024 - Poster 3584. Go to original source...
    23. Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24(10):2475-2484. doi: 10.1093/annonc/mdt226. Epub 2013 Jun 20. PMID: 23788754; PMCID: PMC3841419. Go to original source... Go to PubMed...
    24. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29-37. Go to original source... Go to PubMed...
    25. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. Journal of Clinical Oncology. 2012;30(28):3499-3506. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.